Retraction Watch has been a great resource for those of us who have been following research misconduct. They widely cover and conduct research on retractions, corrections, and other developments in this space. Unfortunately, there’s been plenty to write about even just within the stem cell and cell therapy arena, which is my primary interest. Think […]
CRISPR gene editing has made rapid progress heading from bench to bedside. Perhaps the fastest has been its progress toward clinical use to combat sickle cell disease. We’ll start with a new paper on one major effort here. CRISPR gene editing. This process often involves cutting DNA, which then can be used as an opening to
Weekly reads: CRISPR sickle cell, Parkinson’s, pig-human chimera concerns Read More »
An important appeals case is pending not just for the defendants Cell Surgical Network, et al., but also for the FDA. It could impact the stem cell field very broadly too. Cell Surgical Network lawsuit status Hopefully, we’ll get a decision before the end of this year. Cell Surgical Network is a large chain of
Goldwater Institute weighs in against FDA on Cell Surgical Network lawsuit appeal Read More »
Many of us first became aware of Vivek Ramaswamy as a Republican candidate for President. He was most well-known before that as a biotech leader. Given that biotech background, I decided to learn more about him. Surprisingly, his biomedical efforts may have started with embryonic stem cells. That caught my attention. This was way back
Vivek Ramaswamy & his surprising stem cell start Read More »
Starting last year the FDA has focused much of its cell therapy oversight resources on birth-related firms, including both clinics and suppliers. The latest warnings went to RenatiLabs & Cell Genuity. Warnings to unproven perinatal cell therapy firms Earlier this summer the agency warned Regenative Labs. There have been quite a few letters to others in this
FDA warns more perinatal cell therapy firms: RenatiLabs & Cell Genuity Read More »
Early during my postdoc I was primarily interested in the role of Myc genes both in cancer and in stem cells, work that later included embryonic stem cells. These cells are often called ES cells. At first I first started studying N-Myc in neural stem cells using a conditional knockout approach. However, soon after I was
Weekly reads: embryonic stem cells, Parkinson’s, Alzheimer’s Read More »
It feels like I’ve been writing about the Florida clinic US Stem Cell for a very long time. The FDA has been aware of them for about as long. It was only after reports of patient injuries that the FDA at last took action on US Stem Cell and its subsidiary US Stem Cell Clinic. Several
Did US Stem Cell Clinic defy FDA injunction? New injured patient suit sparks questions Read More »
Australian biotech Mesoblast has had a rollercoaster ride working toward FDA approval of its mesenchymal cell therapy product remestemcel-L. They are seeking approval for use in patients with graft-versus-host disease (GvHD). More specifically, it is intended for pediatric patients with steroid-refractory acute graft versus host disease, or SR-aGVHD. This is a serious condition and new treatment
Hoping for approval, Mesoblast says FDA wants new remestemcel-L trial Read More »
Where do things stand with the investigative approach of stem cells for diabetes? 33% of Type 1 Diabetes Patients Insulin-Free With Stem Cells, Medscape. Not the best headline given the few number of participants here. If your study has only two subjects and one responds, someone is going to say, “50% of people had a
Weekly reads: Vertex stem cells for diabetes update, new CRISPR , immortality Read More »
There seems to be a never-ending supply of stem cell for hair loss research but a new article invokes a novel mechanism. Stem cell for hair loss research and cell mechanics Here’s a recent news item about a PNAS paper: Coaxing hair growth in aging hair follicle stem cells, NW Now. A common theme is things
Weekly reads: stem cell for hair loss, clinic lawsuit update, 2 big retractions Read More »